How does COVID-19 affect prostate cancer?

Published Date: 14 Mar 2023

As the COVID-19 pandemic spreads, access to and delivery of health services has been disrupted like never before. How has it affected the treatment of prostate cancer?

Read Full News

Latest News

S2 Episode 5: HER2 Low Testing in the ADC Era

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

HF With Improved Ejection Fraction

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

S2 Episode 6: A Futuristic Vision for Treating Myelofibrosis

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Radiofrequency Ablation: A First-Line Treatment Option

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

S2 Episode 5: DNA Repair and Replication Stress in Endometrial Cancer

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

May 09 2025 This Week in Cardiology

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

News All Time

Spinal Muscular Atrophy: 5 Things to Know

SMA ranges from mild with slow progression to severe with loss of life in childhood. These five things to know are crucial to understanding the types, causes, diagnosis, and latest treatments.

Managing Familial Hypercholesterolemia in Primary Care

Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.

S2 Episode 1: Hormonal Therapy Updates in Metastatic Endometrial Cancer

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

S2 Episode 2: Endometrial Cancer Disparities: Access to Care and Trials

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

IgA Nephropathy: 5 Differential Diagnoses to Know

IgAN diagnosis is complex, and differentiation from other glomerulopathies is critical. Consider these five important differentials to ensure timely diagnosis and appropriate treatment.

Q&A: Are You Sure the Diagnosis Is IgA Nephropathy?

Arnold B. Alper, MD, discusses the IgA nephropathy differential diagnosis.

SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer

Dr Avan Armaghani discusses the clinical impact of several studies presented at SABCS.

Key Updates in Early Breast Cancer From SABCS 2024

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

More Than Hives: Discussing Chronic Spontaneous Urticaria

Dermatologists discuss common roadblocks in communicating with patients with chronic spontaneous urticaria, who often search for a cause they can fix for a condition lacking in community resources.

Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes?

A commentary on the need for better trials and long-term data for the myosin inhibitors aficamten and mavacamten in obstructive hypertrophic cardiomyopathy.

New Directions in Anemia and Related Disorders From ASH 2024

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Episode 6: HER2-Ultra-Low Breast Cancer

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Growth Hormone and the Thyroid Gland: A Complex Relationship

Drs Kaniksha Desai and Laurence Katznelson discuss the complex relationship between growth hormone and the thyroid gland.

ACR 2024: Key Insights on Updated Lupus Nephritis Guidelines

Dr Bella Mehta reviews new guidance on frequent monitoring, triple therapy, early biopsy, and reduced steroids for better outcomes.

Episode 5: Sequencing of ADCs for Metastatic HER2-Low Disease

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Glomerular Disease Highlights From ASN Kidney Week 2024

Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.

Recommended News For You

Targeted Combination Shows Promise in Metastatic Kidney Cancer

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

Certain Oral Bacteria May Be a Risk Factor for Head and Neck Cancer

A new theranostic drug targets different cancer types.

Decrease seen in in situ breast cancer since 2009

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

Recommended Articles For You

Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care 

Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management 

Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology 

Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Obesity linked to subsequent neoplasms in childhood cancer survivors

2.

We don't all need regular skin cancer screening?but you can know your risk and check yourself

3.

Global inequalities found in cancer research funding

4.

A US health panel advises starting mammograms at age 40 rather than 50.

5.

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes

1.

The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition

2.

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications

3.

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring

4.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

5.

The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

2.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

4.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

5.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot